196612-93-8
Chemical Structure
Falnidamol
Synonym(s): BIBX 1382
- CAS No.: 196612-93-8
- Formula:C18H19ClFN7
- Molecular Weight:387.84
IUPAC Name: N8-(3-chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine
InChIKey: FTFRZXFNZVCRSK-UHFFFAOYSA-N
SMILES: ClC1=CC(NC2=NC=NC3=CN=C(NC(CC4)CCN4C)N=C23)=CC=C1F
Biological Activity: Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Falnidamol | 98.36% | Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Falnidamol (Standard) | ≥98% | Falnidamol (Standard) is the analytical standard of Falnidamol. This product is intended for research and analytical applications. Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.98
HY-110039BIBX 1382 dihydrochloride -
Similarity Score 0.72
HY-103438BIBU1361 -
Similarity Score 0.71
HY-103438ABIBU1361 dihydrochloride -
Similarity Score 0.56
HY-103440REGFR/ErbB-2/ErbB-4 inhibitor-3 (Standard) -
Similarity Score 0.54
HY-Z2553Afatinib impurity 5 -
Similarity Score 0.54
HY-Z4780Dacomitinib impurity 3 -
Similarity Score 0.53
HY-100064RO-Desmethyl gefitinib (Standard) -
Similarity Score 0.53
HY-Z4741Afatinib impurity 16 -
Similarity Score 0.53
HY-Z4533Afatinib impurity 6 -
Explore the MedChemAI to find more analogs
References
- [1]. Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. [Content Brief]
- [2]. Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9. [Content Brief]
